Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
KRas is frequently mutated in multiple cancer types; identifying drugs to treat such cancers is a good therapeutic strategy. Here, the authors perform a synthetic lethal screen in mice and show that inhibiting Plk1 and ROCK results in the inhibition of tumour growth by increasing expression of the t...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms11363 |